According to a recent LinkedIn post from Latigo Biotherapeutics, the company is bringing on Neha Krishnamohan as chief financial officer and chief business officer. The post highlights her more than 15 years of experience in healthcare investment banking and biotech financial leadership, including prior roles as CFO and EVP of Corporate Development at Artiva Biotherapeutics and Kinnate Biopharma.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post notes that Krishnamohan played a lead role in Artiva’s transition to the public markets and began her career in healthcare investment banking and M&A at Goldman Sachs. This background suggests Latigo may be positioning itself for more sophisticated capital markets activity, potentially including future private or public financing as it advances its non opioid pain pipeline.
For investors, the appointment points to a strategic focus on corporate development, financing, and potential partnering given her dual CFO and CBO responsibilities. As shared in the post, tying this leadership addition to progress on a differentiated, non opioid pain portfolio may signal an intention to scale the platform and increase Latigo’s visibility within the competitive biopharma and pain management landscape.